CN108026059A - 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物 - Google Patents

四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物 Download PDF

Info

Publication number
CN108026059A
CN108026059A CN201680033152.9A CN201680033152A CN108026059A CN 108026059 A CN108026059 A CN 108026059A CN 201680033152 A CN201680033152 A CN 201680033152A CN 108026059 A CN108026059 A CN 108026059A
Authority
CN
China
Prior art keywords
crystal form
anavex19
metabolin
diphenyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680033152.9A
Other languages
English (en)
Chinese (zh)
Inventor
P·约克
L·A·伦纳德
D·M·莱杰
L·S·丹特里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anavex Life Sciences Corp
Original Assignee
Anavex Life Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anavex Life Sciences Corp filed Critical Anavex Life Sciences Corp
Priority to CN202411518463.7A priority Critical patent/CN119390667A/zh
Publication of CN108026059A publication Critical patent/CN108026059A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
CN201680033152.9A 2015-07-22 2016-07-19 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物 Pending CN108026059A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411518463.7A CN119390667A (zh) 2015-07-22 2016-07-19 四氢-n,n-二甲基-2,2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195486P 2015-07-22 2015-07-22
US62/195,486 2015-07-22
PCT/IB2016/001181 WO2017013498A2 (en) 2015-07-22 2016-07-19 Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411518463.7A Division CN119390667A (zh) 2015-07-22 2016-07-19 四氢-n,n-二甲基-2,2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物

Publications (1)

Publication Number Publication Date
CN108026059A true CN108026059A (zh) 2018-05-11

Family

ID=57833871

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411518463.7A Pending CN119390667A (zh) 2015-07-22 2016-07-19 四氢-n,n-二甲基-2,2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物
CN201680033152.9A Pending CN108026059A (zh) 2015-07-22 2016-07-19 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202411518463.7A Pending CN119390667A (zh) 2015-07-22 2016-07-19 四氢-n,n-二甲基-2,2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物

Country Status (7)

Country Link
US (4) US10413519B2 (enExample)
EP (2) EP3325456B1 (enExample)
JP (3) JP7304043B2 (enExample)
CN (2) CN119390667A (enExample)
CA (1) CA2986349A1 (enExample)
HK (1) HK1247926A1 (enExample)
WO (1) WO2017013498A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023208133A1 (zh) * 2022-04-29 2023-11-02 苏州科睿思制药有限公司 布拉美森盐酸盐的晶型及其制备方法和用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426754B2 (en) 2017-06-14 2019-10-01 Anavex Life Sciences Corp. Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease
AU2017418247B2 (en) * 2017-06-14 2023-12-14 Anavex Life Sciences Corp. ANAVEX2-73 for the treatment of Alzheimer's disease
WO2019200345A1 (en) * 2018-04-12 2019-10-17 Anavex Life Sciences Corp. A2-73 crystalline polymorph compositions of matter and methods of use thereof
EP3794345B1 (en) 2018-05-18 2025-02-26 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
EP4100398A1 (en) 2020-02-04 2022-12-14 Teva Pharmaceuticals International GmbH Solid state forms of blarcamesine salts
US12018005B1 (en) * 2023-07-25 2024-06-25 Egis Gyógyszergyár Zrt. Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030983A1 (en) * 1996-02-21 1997-08-28 Alexandre Vamvakides Tetrahydro-n,n-dimethyl-2,2-diphenyl-3-feranemethanamine, its enantiomers, and their pharmaceutically acceptable acid addition salts
CN102325529A (zh) * 2009-02-26 2012-01-18 亚历山大·瓦姆瓦基德斯 显示原型细胞保护活性并且还显示抗癌活性的在细胞机制方面具有促凋亡和/或抗凋亡特性的西格玛(σ)受体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB9804379D0 (en) 1998-03-02 1998-04-22 Bradford Particle Design Ltd Method of particle formation
GB9810559D0 (en) 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
TW586963B (en) 2001-07-20 2004-05-11 Nektar Therapeutics Uk Ltd Method and apparatus for preparing target substance in particulate form and fluid inlet assembly for said apparatus
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
GB201005623D0 (en) 2010-04-01 2010-05-19 Vantia Ltd New polymorph
GR1007686B (el) * 2011-07-08 2012-09-12 Αλεξανδρος Δημητριου Βαμβακιδης Συνθεση των (+) και (-) 1-(5,5-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης, (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης και (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν-μεθυλομεθυλαμινης
CN103539783A (zh) * 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
GR1008233B (el) 2013-03-28 2014-06-23 Αλεξανδρος Δημητριου Βαμβακιδης Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες
CN116687906A (zh) 2015-07-22 2023-09-05 阿纳韦克斯生命科学公司 ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途
US10426754B2 (en) 2017-06-14 2019-10-01 Anavex Life Sciences Corp. Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030983A1 (en) * 1996-02-21 1997-08-28 Alexandre Vamvakides Tetrahydro-n,n-dimethyl-2,2-diphenyl-3-feranemethanamine, its enantiomers, and their pharmaceutically acceptable acid addition salts
CN102325529A (zh) * 2009-02-26 2012-01-18 亚历山大·瓦姆瓦基德斯 显示原型细胞保护活性并且还显示抗癌活性的在细胞机制方面具有促凋亡和/或抗凋亡特性的西格玛(σ)受体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDREANNE BOUCHARD ET AL.: "Ways of manipulating the polymorphism of glycine during supercritical fluid crystallisation", 《J. OF SUPERCRITICAL FLUIDS》 *
VALENTINE LAHMY ET AL.: "Blockade of Tau Hyperphosphorylation and Aβ1-42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and r1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer"s Disease", 《NEUROPSYCHOPHARMACOLOGY》 *
VANESSA VILLARD ET AL.: "Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative", 《JOURNAL OF PSYCHOPHARMACOLOGY》 *
宋航主编: "《制药分离工程》", 31 August 2011, 华东理工大学出版社 *
王广基等主编: "《中国医药科学技术战略与政策研究》", 31 May 2002, 中国医药科技出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023208133A1 (zh) * 2022-04-29 2023-11-02 苏州科睿思制药有限公司 布拉美森盐酸盐的晶型及其制备方法和用途

Also Published As

Publication number Publication date
JP2023083528A (ja) 2023-06-15
EP3325456A2 (en) 2018-05-30
EP3325456A4 (en) 2019-01-23
US20190350892A1 (en) 2019-11-21
WO2017013498A2 (en) 2017-01-26
WO2017013498A3 (en) 2017-03-02
JP2018524307A (ja) 2018-08-30
EP4616852A3 (en) 2025-10-22
US20210220321A1 (en) 2021-07-22
EP3325456B1 (en) 2025-09-03
US10966952B2 (en) 2021-04-06
EP4616852A2 (en) 2025-09-17
US11661405B2 (en) 2023-05-30
US10413519B2 (en) 2019-09-17
JP7304043B2 (ja) 2023-07-06
JP2021073300A (ja) 2021-05-13
HK1247926A1 (zh) 2018-10-05
CA2986349A1 (en) 2017-01-26
JP7492781B2 (ja) 2024-05-30
US20230278973A1 (en) 2023-09-07
US20180169060A1 (en) 2018-06-21
CN119390667A (zh) 2025-02-07

Similar Documents

Publication Publication Date Title
JP7492781B2 (ja) テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミンヒドロクロリドの結晶形態、かかる形態の作製方法およびその薬学的組成物
CN113527203B (zh) 乐伐替尼甲磺酸盐的晶型及其制备方法和用途
Cui et al. Naringenin cocrystals prepared by solution crystallization method for improving bioavailability and anti-hyperlipidemia effects
BRPI0507476B1 (pt) monoidrato cristalino, sua composição farmacêutica e seu uso
US20180230140A1 (en) Multicomponent crystals of dasatinib with menthol or vanillin
Cheng et al. Micronization of etoposide using solution-enhanced dispersion by supercritical CO2
JP6501773B2 (ja) 結晶形態のダサチニブの塩
JP6126040B2 (ja) ニコサミド（Ｎｉｃｏｕｓａｍｉｄｅ）化合物の五つの晶型、その製法やその薬物組合と用途
CN113717110A (zh) 二氨基甲酰胺化合物的固体形式、其组合物及其使用方法
KR20200011943A (ko) 헤테로시클리덴 아세트아미드 유도체의 결정
Khodov et al. Exploring the temperature-dependent proportions of lidocaine conformers equilibria in supercritical carbon dioxide via NOESY
Kudryashova et al. Micronization of levofloxacin by supercritical antisolvent precipitation
Zhao et al. Co‐Crystal of Paracetamol and Trimethylglycine Prepared by a Supercritical CO2 Anti‐Solvent Process
CN112500385B (zh) 一种制备香叶木素衍生物超细微粒的方法
CN105418622B (zh) 一种青蒿素衍生物及其合成方法和应用
CA2837266A1 (en) Amorphous ritonavir co-precipitated
CN106854203A (zh) 枸橼酸舒芬太尼的新晶型及其制备方法
CN105777656B (zh) 萘普替尼对甲苯磺酸盐的β晶型及制备方法和含有其的药物组合物
WO2015170827A1 (ko) 실로도신 감마형 결정의 제조방법
CN105503852A (zh) 噻唑甲酰胺氮氧化物
Vennapu et al. Polymorphic characterization of tramadol hydrochloride using differential scanning calorimetry
CN101384584A (zh) 贝西吡啶盐酸盐的晶型、制备方法及其应用
JP2013518889A (ja) （Ｓ）−１−（４−（５−シクロプロピル−１Ｈ−ピラゾール−３−イルアミノ）ピロロ［１，２−ｆ］［１，２，４］トリアジン−２−イル）−Ｎ−（６−フルオロピリジン−３−イル）−２−メチルピロリジン−２−カルボキサミドの結晶形
Tango et al. Challenge for Stable Production on Oral Formulation Manufacturing Process
CN104797579A (zh) 噻托溴铵溶剂化物的稳定化

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1247926

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20180511

RJ01 Rejection of invention patent application after publication